Literature DB >> 28956341

Targeting Phosphodiesterases in Pharmacotherapy for Substance Dependence.

Rui-Ting Wen1, Jian-Hui Liang2, Han-Ting Zhang3,4,5.   

Abstract

Substance dependence is a chronic relapsing brain disorder associated with adaptational changes in synaptic plasticity and neuronal functions. The high levels of substance consumption and relapse rate suggest more reliable medications are in need to better address the underlying causes of this disease. It has been well established that the intracellular second messengers cyclic AMP (cAMP) and cyclic GMP (cGMP) and their signaling systems play an important role in the molecular mechanisms of substance taking behaviors. On this basis, the phosphodiesterase (PDE) superfamily, which crucially controls cyclic nucleotide levels by catalyzing their hydrolysis, has been proposed as a novel class of therapeutic targets for substance use disorders. This chapter reviews the expression patterns of PDEs in the brain with regard to neural structures underlying the dependent process and highlights available evidence for a modulatory role of PDEs in substance dependence.

Entities:  

Keywords:  Central nervous system; Phosphodiesterase; Signal transduction; Substance dependence; cAMP; cGMP

Mesh:

Substances:

Year:  2017        PMID: 28956341     DOI: 10.1007/978-3-319-58811-7_15

Source DB:  PubMed          Journal:  Adv Neurobiol


  2 in total

Review 1.  Cyclic nucleotide phosphodiesterases: potential therapeutic targets for alcohol use disorder.

Authors:  Rui-Ting Wen; Fang-Fang Zhang; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2018-04-16       Impact factor: 4.530

2.  The general law of plasma proteome alterations occurring in the lifetime of Chinese individuals reveals the importance of immunity.

Authors:  Xiaolin Ni; Juan Jiao; Ze Yang; Zhaoping Wang; Nan Nan; Danni Gao; Liang Sun; Xiaoquan Zhu; Qi Zhou; Nan Zhang; Zhu Wu; Shenqi Zhang; Huiping Yuan
Journal:  Aging (Albany NY)       Date:  2022-09-07       Impact factor: 5.955

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.